# OnCo record b-resistance (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-resistance/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-resistance" ;
  schema:name "Acquired resistance to every therapy"@en ;
  schema:description "Nearly every targeted therapy stops working within months to a few years as the tumour adapts."@en ;
  schema:url <https://onco.cc/bottlenecks/b-resistance/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1713137>, <https://doi.org/10.1038/s41586-019-1730-1> ;
  onco:related <https://onco.cc/ideas/idea-dual-payload-first/>, <https://onco.cc/ideas/idea-payload-switching/>, <https://onco.cc/ideas/idea-btk-degrader-frontline/>, <https://onco.cc/ideas/idea-ctdna-switch-generalised/>, <https://onco.cc/collections/genie/>, <https://onco.cc/ideas/idea-bio1-mandatory-progression-biopsy/>, <https://onco.cc/ideas/idea-bio1-open-resistance-atlas/>, <https://onco.cc/ideas/idea-bio1-upfront-bypass-combination/>, <https://onco.cc/ideas/idea-bio1-pre-randomised-sequencing-trials/>, <https://onco.cc/ideas/idea-bio1-antigen-mapping-at-progression/>, <https://onco.cc/ideas/idea-bio1-dual-antigen-adc-escape/>, <https://onco.cc/ideas/idea-bio1-adaptive-car-antigen-switch/>, <https://onco.cc/ideas/idea-bio1-drug-holiday-resensitisation/>, <https://onco.cc/ideas/idea-bio1-persister-ferroptosis/>, <https://onco.cc/ideas/idea-bio1-epigenetic-persister-blockade/>, <https://onco.cc/ideas/idea-bio1-mutagenesis-blockade-rev1/>, <https://onco.cc/ideas/idea-bio1-stress-response-blockade/>, <https://onco.cc/ideas/idea-bio1-senolytics-after-therapy/>, <https://onco.cc/ideas/idea-bio1-persister-metabolic-vulnerability/>, <https://onco.cc/ideas/idea-bio1-molecular-progression-add-on/>, <https://onco.cc/ideas/idea-bio1-alternating-schedules/>, <https://onco.cc/ideas/idea-bio1-resistance-mutation-vaccine/>, <https://onco.cc/ideas/idea-bio1-mechanism-matched-access/>, <https://onco.cc/ideas/idea-bio1-resistance-platform-trial/>, <https://onco.cc/ideas/idea-bio1-slfn11-payload-guidance/>, <https://onco.cc/ideas/idea-bio1-stromal-resistance-blockade/>, <https://onco.cc/ideas/idea-bio1-real-world-resistance-surveillance/>, <https://onco.cc/ideas/idea-bio1-approval-linked-progression-sampling/>, <https://onco.cc/ideas/idea-bio1-drug-exposure-sanctuary-mapping/>, <https://onco.cc/ideas/idea-bio1-immunopeptidome-timing/>, <https://onco.cc/ideas/idea-moon-closed-loop-adaptive-therapy/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/dual-payload-adc/>, <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/adc-payload-neutralizer/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/bgb-16673/>, <https://onco.cc/drugs/amivantamab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/beone/>, <https://onco.cc/companies/nurix/>, <https://onco.cc/companies/sutro-biopharma/>, <https://onco.cc/companies/mersana/>, <https://onco.cc/companies/systimmune/> ;
  onco:institutions <https://onco.cc/institutions/moffitt/>, <https://onco.cc/institutions/mskcc/> ;
  onco:terms <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/c797s/>, <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/efflux-pump/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/endocrine-resistance/>, <https://onco.cc/terms/bcg-unresponsive/>, <https://onco.cc/terms/adc-sequencing/> ;
  onco:trials <https://onco.cc/trials/serena-6/>, <https://onco.cc/trials/mariposa/>, <https://onco.cc/trials/flaura2/>, <https://onco.cc/trials/bruin-cll-321/>, <https://onco.cc/trials/cadance-304/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-vasan-nature/> .